ZIOPHARM Oncology (ZIOP) Showing Signs Of A Dead Cat Bounce Today
Trade-Ideas LLC identified
(
) as a "dead cat bounce" (down big yesterday but up big today) candidate. In addition to specific proprietary factors, Trade-Ideas identified ZIOPHARM Oncology as such a stock due to the following factors:
- ZIOP has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $21.4 million.
- ZIOP has traded 112,223 shares today.
- ZIOP is up 3.6% today.
- ZIOP was down 5.5% yesterday.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in ZIOP with the Ticky from Trade-Ideas. See the FREE profile for ZIOP NOW at Trade-Ideas
More details on ZIOP:
ZIOPHARM Oncology, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of cancer therapies that address unmet medical needs through synthetic immuno-oncology. Currently there is 1 analyst that rates ZIOPHARM Oncology a buy, 1 analyst rates it a sell, and 3 rate it a hold.
The average volume for ZIOPHARM Oncology has been 2.6 million shares per day over the past 30 days. ZIOPHARM Oncology has a market cap of $902.3 million and is part of the health care sector and drugs industry. The stock has a beta of 2.46 and a short float of 29.6% with 11.28 days to cover. Shares are down 15.8% year-to-date as of the close of trading on Monday.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Analysis:
rates ZIOPHARM Oncology as a
. The company's weaknesses can be seen in multiple areas, such as its weak operating cash flow and generally disappointing historical performance in the stock itself.
Highlights from the ratings report include:
- Net operating cash flow has significantly decreased to -$16.08 million or 65.47% when compared to the same quarter last year. In addition, when comparing to the industry average, the firm's growth rate is much lower.
- ZIOP has underperformed the S&P 500 Index, declining 24.10% from its price level of one year ago. The fact that the stock is now selling for less than others in its industry in relation to its current earnings is not reason enough to justify a buy rating at this time.
- The company's current return on equity greatly increased when compared to its ROE from the same quarter one year prior. This is a signal of significant strength within the corporation. Compared to other companies in the Biotechnology industry and the overall market, ZIOPHARM ONCOLOGY INC's return on equity significantly trails that of both the industry average and the S&P 500.
- ZIOPHARM ONCOLOGY INC reported significant earnings per share improvement in the most recent quarter compared to the same quarter a year ago. This company has reported somewhat volatile earnings recently. But, we feel it is poised for EPS growth in the coming year. During the past fiscal year, ZIOPHARM ONCOLOGY INC reported poor results of -$1.01 versus -$0.32 in the prior year. This year, the market expects an improvement in earnings (-$0.43 versus -$1.01).
- The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Biotechnology industry. The net income increased by 84.6% when compared to the same quarter one year prior, rising from -$78.23 million to -$12.02 million.
- You can view the full ZIOPHARM Oncology Ratings Report.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
